Foley & Lardner LLP Partner Jessica Lochmann is quoted in the Law360 article, “New Buyback Rules Put Companies’ Motives Under Spotlight,” discussing new disclosures mandated by the U.S. Securities and Exchange Commission that will see greater scrutiny placed upon company buyback programs.
Companies should prepare to justify their buyback programs in greater detail, and Lochmann said to limit liability for misleading disclosures, corporate executives and boards should carefully examine whether their communications on buyback policies are materially accurate and complete.
“And those reasons and rationales may change over time,” Lochmann added. “I don’t think that language should be boilerplate.”
(Subscription required)
People
Related News
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."
July 18, 2025
In the News
Aaron Maguregui Highlights Potential Compliance Concerns in Pre-Tax Wellness Claims
Foley & Lardner LLP partner Aaron Maguregui commented in The New York Times article, "Hot Dogs for Insomnia? A Kennedy Aide's Start-Up Can Get You a Tax Break," sharing insight on the growing use of medical necessity letters to support tax-advantaged purchases of wellness products.